# ORZEYFUL (oveporexton) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/oveporexton

> The FDA approved ORZEYFUL (oveporexton), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on August 5, 2026 for to treat narcolepsy type 1.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is ORZEYFUL (oveporexton) FDA approved?

Yes. The FDA approved ORZEYFUL (oveporexton), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on August 5, 2026 for to treat narcolepsy type 1. FDA novel drug approvals: "Orzeyful | oveporexton | 8/5/2026 | To treat narcolepsy type 1" [Calendar and source filings](https://sec-api.dev/pdufa/oveporexton)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/oveporexton#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ORZEYFUL (oveporexton) |
| Codes | TAK-861 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | nt1 in adult patients, [narcolepsy type 1](https://sec-api.dev/indications/narcolepsy-type-1), excessive daytime sleepiness in nt1, To treat narcolepsy type 1 |
| Modality |  |
| FDA designations | breakthrough, orphan, priority review |

## Timeline

### June 3, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Narcolepsy Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06470828 (A Study of TAK-861 for the Treatment of Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-08-31." https://clinicaltrials.gov/study/NCT06470828

### Feb 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-05-26, last confirmed 2026-05-26.
- Press release filed with the SEC (EX-99) (accession 0001395064-26-000162): "Oveporexton was generally well-tolerated with a safety profile consistent across clinical studies to date. - In February 2026, Takeda announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton for the treatment of NT1." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm

### March 31, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact. Stage: 3. Indication: excessive daytime sleepiness in NT1.
- First seen 2026-05-26, last confirmed 2026-06-17.
- Press release filed with the SEC (EX-99) (accession 0001395064-26-000162): "Oveporexton previously received Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in NT1 from the U.S. FDA and the Center for Drug Evaluation of China's National Medical Products Administration. - In March 2026, Takeda announced that it submitted the NDA to the Japanese Ministry of Health, Labour and Welfare (MHLW) for oveporexton for the expected indication of NT1." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm
- SEC Form 10-K (accession 0001395064-26-000177): "In the fiscal year ended March 31, 2026, we submitted New Drug Applications ("NDAs") in the U.S. for oveporexton and rusfertide following successful Phase 3 clinical trial results." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

### Q3 2026: PDUFA date

- Status: completed, approved. Date confidence: quarter.
- First seen 2026-02-10, last confirmed 2026-06-17.
- Press release filed with the SEC (EX-99) (accession 0001395064-26-000162): "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm
- SEC Form 10-K (accession 0001395064-26-000177): "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm
- SEC Form 8-K (accession 0001395064-26-000005): "-The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year" https://www.sec.gov/Archives/edgar/data/1395064/000139506426000005/form6k_021026.htm
- SEC Form 8-K (accession 0001395064-26-000005): "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000005/form6k_021026.htm

### August 5, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat narcolepsy type 1.
- First seen 2026-08-06, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Orzeyful | oveporexton | 8/5/2026 | To treat narcolepsy type 1" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- openFDA Drugs@FDA: "NDA220860 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20260805, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product ORZEYFUL (OVEPOREXTON)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220860%22
- SEC Form 8-K (accession 0001395064-26-000329): "OSAKA, Japan and CAMBRIDGE, Massachusetts, August 5, 2026 - Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people's lives." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000329/form6k_080526.htm
- SEC Form 8-K (accession 0001395064-26-000345): "-In August 2026, Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL for the treatment of NT1 in adult patients." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/form6k-2_102926.htm

### August 31, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Narcolepsy Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06470828 (A Study of TAK-861 for the Treatment of Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-08-31." https://clinicaltrials.gov/study/NCT06470828?tab=results

## Same indication

- [Neuropeptide](https://sec-api.dev/pdufa/neuropeptide) (ALKS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/oveporexton.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ORZEYFUL (oveporexton) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/oveporexton

```bibtex
@misc{secapidev_pdufa_oveporexton_20261116,
  title        = {ORZEYFUL (oveporexton) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/oveporexton}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_oveporexton_20261116","title":"ORZEYFUL (oveporexton) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/oveporexton","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
